Amoy Diagnostics Co., Ltd.

Shenzhen Stock Exchange 300685.SZ

Amoy Diagnostics Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: 16.82%

Amoy Diagnostics Co., Ltd. Return on Capital Employed (ROCE) is 16.82% for the year ending December 31, 2023, a -11.84% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Amoy Diagnostics Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 19.08%, a 4.98% change year over year.
Amoy Diagnostics Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 18.17%, a 3.55% change year over year.
Amoy Diagnostics Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 17.55%, a -5.27% change year over year.
Amoy Diagnostics Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 18.52%, a -0.56% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Shenzhen Stock Exchange: 300685.SZ

Amoy Diagnostics Co., Ltd.

CEO	Ms. Ying Chen
IPO Date	Aug. 3, 2017
Location	China
Headquarters	39 Dingshan Road
Employees	1,119
Sector	Healthcare
Industries Biotechnology

Description

Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on molecular diagnostics for oncology precision medicine in China and internationally. The company offers NGS, real-time PCR, FISH, and extraction assays. Amoy Diagnostics Co., Ltd. was founded in 2008 and is based in Xiamen, China.

Key trends

Past 5 years